Drugs / JL15003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07497373 | Nov 2022 → May 2024 | glioblastoma | Jecho Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07501559 | Apr 2026 → Apr 2030 expected | glioblastoma | Jecho Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-11 | Jecho Biopharmaceuticals Co., Ltd. | Jechobio JL15003 Secures Dual Recognition with Oral Presentations at Leading CSCO and SNO Oncology Conferences jechobio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JL15003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07501559 ↗ |
| Known as | JL15003 Injection | “The goal of this clinical trial is to evaluate the safety and efficacy of JL15003 Injection in subjects with recurrent glioblastoma (rGMB).” NCT07501559 ↗ |
| Route | Other | “Single intratumoral administration of JL15003 Injection” NCT07497373 ↗ |